McCartney J E, Tai M S, Hudziak R M, Adams G P, Weiner L M, Jin D, Stafford W F, Liu S, Bookman M A, Laminet A A
Creative BioMolecules Inc., Hopkinton, MA 01748, USA.
Protein Eng. 1995 Mar;8(3):301-14. doi: 10.1093/protein/8.3.301.
Single-chain Fv fusions with C-terminal cysteinyl peptides (sFv') have been engineered using model sFv proteins based upon the 26-10 anti-digoxin IgG and 741F8 anti-c-erbB-2 IgG monoclonal antibodies. As part of the 741F8 sFv construction process, the PCR-amplified 741F8 VH gene was modified in an effort to correct possible primer-induced errors. Genetic replacement of the N-terminal beta-strand sequence of 741F8 VH with that from the FR1 of anti-c-erbB-2 520C9 VH resulted in a dramatic improvement of sFv folding yields. Folding in urea-glutathione redox buffers produced active sFv' with a protected C-terminal sulfhydryl, presumably as the mixed disulfide with glutathione. Disulfide-bonded (sFv')2 homodimers were made by disulfide interchange or oxidation after reductive elimination of the blocking group. Both 26-10 (sFv')2 and 741F8 (sFv')2 existed as stable dimers that were well behaved in solution, whereas 741F8 sFv and sFv' exhibited considerable self-association. The 741F8 sFv binds to the extracellular domain (ECD) of the c-erbB-2 oncogene protein, which is often overexpressed in breast cancer and other adenocarcinomas. The recombinant ECD was prepared to facilitate the analysis of 741F8 binding site properties; the cloned ECD gene, modified to encode a C-terminal Ser-Gly-His6 peptide, was transfected into Chinese hamster ovary cells using a vector that also expressed dihydrofolate reductase to facilitate methotrexate amplification. Optimized cell lines expressed ECD-His6 at high levels in a cell bioreactor; after isolation by immobilized metal affinity chromatography, final ECD yields were as high as 47 mg/l. An animal tumor model complemented physicochemical studies of 741F8 species and indicated increased tumor localization of the targeted 741F8 (sFv')2 over other monovalent 741F8 species.
已使用基于26 - 10抗地高辛IgG和741F8抗c - erbB - 2 IgG单克隆抗体的模型单链抗体片段(sFv)构建了与C末端半胱氨酸肽融合的单链Fv(sFv')。作为741F8 sFv构建过程的一部分,对PCR扩增的741F8 VH基因进行了修饰,以纠正可能的引物诱导错误。用抗c - erbB - 2 520C9 VH的FR1中的N末端β链序列对741F8 VH的N末端β链序列进行基因置换,使sFv折叠产率显著提高。在尿素 - 谷胱甘肽氧化还原缓冲液中折叠产生了具有受保护的C末端巯基的活性sFv',推测是作为与谷胱甘肽的混合二硫键。通过还原消除保护基团后进行二硫键交换或氧化制备了二硫键连接的(sFv')2同源二聚体。26 - 10(sFv')2和741F8(sFv')2均以稳定的二聚体形式存在,在溶液中表现良好,而741F8 sFv和sFv'表现出相当程度的自缔合。741F8 sFv与c - erbB - 2癌基因蛋白的细胞外结构域(ECD)结合,该蛋白在乳腺癌和其他腺癌中常过度表达。制备重组ECD以促进对741F8结合位点特性的分析;将经修饰以编码C末端Ser - Gly - His6肽的克隆ECD基因,使用同时表达二氢叶酸还原酶以促进甲氨蝶呤扩增的载体转染到中国仓鼠卵巢细胞中。优化的细胞系在细胞生物反应器中高水平表达ECD - His6;通过固定化金属亲和色谱分离后,最终ECD产量高达47 mg/l。动物肿瘤模型补充了对741F8种类的物理化学研究,并表明靶向的741F8(sFv')2在肿瘤中的定位比其他单价741F8种类增加。